Inovio Pharmaceuticals Inc (INO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has a cash flow conversion efficiency ratio of 2.795x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.57 Million) by net assets ($-7.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INO company net worth for the company's overall valuation and market capitalisation.
Inovio Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inovio Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Inovio Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KPS Corporation
KQ:256940
|
-0.036x |
|
Falcon Metals Ltd
AU:FAL
|
-0.177x |
|
BIEN SPAREB.AS NK 34375
F:JX0
|
-0.180x |
|
Sterling Tools Limited
NSE:STERTOOLS
|
0.055x |
|
LBG MEDIA PLC LS -001
F:S83
|
0.059x |
|
West Vault Mining
V:WVM
|
-0.004x |
|
Interlink Communication Public Company Limited
BK:ILINK
|
0.051x |
|
Auburn National Bancorporation Inc
NASDAQ:AUBN
|
0.038x |
Annual Cash Flow Conversion Efficiency for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. View latest Inovio Pharmaceuticals Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.50 Million | $-104.08 Million | -1.519x | -43.36% |
| 2023-12-31 | $117.35 Million | $-124.37 Million | -1.060x | -8.99% |
| 2022-12-31 | $222.36 Million | $-216.22 Million | -0.972x | -80.16% |
| 2021-12-31 | $399.67 Million | $-215.71 Million | -0.540x | -39.84% |
| 2020-12-31 | $461.14 Million | $-177.98 Million | -0.386x | +97.87% |
| 2019-12-31 | $5.40 Million | $-97.85 Million | -18.104x | -2042.27% |
| 2018-12-31 | $87.03 Million | $-73.55 Million | -0.845x | -90.50% |
| 2017-12-31 | $142.49 Million | $-63.21 Million | -0.444x | +12.51% |
| 2016-12-31 | $123.38 Million | $-62.56 Million | -0.507x | -617.11% |
| 2015-12-31 | $175.93 Million | $-12.44 Million | -0.071x | +73.56% |
| 2014-12-31 | $111.54 Million | $-29.82 Million | -0.267x | +8.04% |
| 2013-12-31 | $52.90 Million | $-15.38 Million | -0.291x | +54.57% |
| 2012-12-31 | $34.86 Million | $-22.31 Million | -0.640x | -55.04% |
| 2011-12-31 | $47.86 Million | $-19.76 Million | -0.413x | -62.86% |
| 2010-12-31 | $47.10 Million | $-11.94 Million | -0.253x | -10.13% |
| 2009-12-31 | $61.18 Million | $-14.08 Million | -0.230x | +60.48% |
| 2008-12-31 | $19.11 Million | $-11.13 Million | -0.582x | -56.97% |
| 2007-12-31 | $31.03 Million | $-11.51 Million | -0.371x | -23.80% |
| 2006-12-31 | $23.50 Million | $-7.04 Million | -0.300x | +42.99% |
| 2005-12-31 | $23.47 Million | $-12.34 Million | -0.526x | -20.20% |
| 2004-12-31 | $15.55 Million | $-6.80 Million | -0.437x | -139.45% |
| 2003-12-31 | $15.05 Million | $-2.75 Million | -0.183x | +86.28% |
| 2002-12-31 | $3.73 Million | $-4.96 Million | -1.331x | +21.06% |
| 2001-12-31 | $4.96 Million | $-8.37 Million | -1.687x | -89.75% |
| 2000-12-31 | $9.89 Million | $-8.79 Million | -0.889x | -66.92% |
| 1999-12-31 | $11.83 Million | $-6.30 Million | -0.532x | +29.85% |
| 1998-12-31 | $8.30 Million | $-6.30 Million | -0.759x | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more